openPR Logo
Press release

Neurofibromatosis (NF) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key players are Pfizer, Novartis, AstraZeneca, Merck, GSK, BioXcel Therapeutics Inc.

06-14-2019 11:33 AM CET | Health & Medicine

Press release from: Pharma Proff

Neurofibromatosis (NF) Therapeutics Pipeline

Neurofibromatosis (NF) Therapeutics Pipeline

Neurofibromatosis (NF) is a genetic disorder that causes tumors on nerve tissues. These are usually non-cancerous, but few can be developed into cancer. The disorder becomes prominent by the age of 10–15 years. The NF is of three types: NF1, NF2, and schwannomatosis. NF1 is caused due to the defect in chromosome 17, NF2 is a result of defect in chromosome 22, and schwannomatosis is a rare form of NF in which people develop multiple tumors consisting of schwann cells on cranial, spinal, and peripheral nerves.

Download the sample report at:

The diagnosis of the disorder is usually in early childhood due to its symptoms such as café-au-lait brown spots on the skin, abnormalities in bone development, appearance of freckles in groin or under armpits, and various others. So, the diagnosis can include genetic testing. Moreover, other ways of diagnosis are physical examination under special lamps, X-rays, computerized tomography (CT) scan, or blood test for NF1; and hearing and audiometry tests for NF2. The cure of the disease is not well-known, but developments are going on for minimizing the symptoms.

Get the detailed analysis report at:

According to the research findings, majority of the pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for NF through the oral route has shown promising results in clinical studies. Moreover, many of the drug candidates are mitogen-activated protein kinase (MEK) inhibitors, which inhibit the growth of tumor cells.
Though there are no marketed products for the disease, there are many drugs in the pipeline. For instance, selumetinib is a MEK inhibitor developed by Array BioPharma, which is under phase 2 clinical trial. Due to many such drug candidates in clinical phases, there is a strong anticipation that the portfolio for NF is going to expand widely in the upcoming years. Moreover, BXCL101 manufactured by BioXcel Therapeutics Inc. received the Orphan Drug Designation from the U.S. Food and Drug Administration (USFDA) for curing NF2.
Some of the key players involved in the development of NF are Pfizer Inc., Novartis International AG, AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, and BioXcel Therapeutics Inc.

Make enquiry before purchase at:

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of NF. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the NF therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to NF.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neurofibromatosis (NF) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key players are Pfizer, Novartis, AstraZeneca, Merck, GSK, BioXcel Therapeutics Inc. here

News-ID: 1775684 • Views: 1178

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for Therapeutics

Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant
Pruritus Drug Market – Key Players are Cara Therapeutics, Enteris BioPharma, N …
The Pruritus Drug Market research report is a significant investigation of changing business sector elements, driving elements, impediments, and limitations that have been considered the most extensive impacts on market development. Adroit investigative devices, for example, Porter’s Five Forces examination, SWOT examination, and Feasibility examination study have likewise been utilized by the report to offer an exhaustive information of the market. It will go about as a key research report
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Global mRNA Cancer Vaccines and Therapeutics Market to 2025| Moderna Therapeutic …
Researchmoz added Most up-to-date research on "Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. mRNA Cancer Vaccines and Therapeutics Market report includes (6 Year Forecast 2019-2025) includes Overview, classification, industry value, price, cost and gross profit. It also offers in-intensity insight of the mRNA Cancer Vaccines and Therapeutics industry masking all vital parameters along with, Drivers, Market Trends, Market Dynamics,
Global Pruritus Therapeutics Market Report 2019 Companies included Actavis, Trev …
Market Reports Company has recently published 7th edition of Pruritus Therapeutics Market Report which covers historic data of year 2013 to 2018 along with a forecast till year 2026. For inquiry or free sample pages email us at: The report provides a comprehensive view on the current state and future prospects of the market which analyzes different strategies for business growth. The global Pruritus Therapeutics market was valued at USD xx
MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Mode …
WiseGuyReports.Com Publish a New Market Research Report On –“ MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics”. Description:- The mRNA Vaccines & Therapeutics industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, mRNA Vaccines & Therapeutics market size to maintain the average annual growth rate of XXX from